Evidence for a cytoskeleton attachment domain at the N‐terminus of the NF2 protein

Neurofibromatosis type 2 is a hereditary cancer syndrome characterized by the development of bilateral vestibular schwannomas. Underlying the disease are inactivating mutations of the NF2 tumor suppressor gene, located on chromosome 22, encoding a 595‐amino‐acid protein. The NF2 protein, also known as merlin or schwannomin, is reported to act as a membrane‐cytoskeleton linking protein. This assumption is based on the homology of the NF2 protein to a group of band 4.1‐related proteins, ezrin, radixin, and moesin. The cytoskeletal association of the NF2 protein has in part been confirmed by its ability to resist extraction from cells by nonionic detergents. We performed detergent extraction on COS cells transfected with NF2 cDNA constructs. The extracts were analyzed by Western blotting and immunofluorescent staining with monoclonal anti‐NF2 antibodies. The results provide evidence for a high‐affinity cytoskeleton attachment domain at amino acids 29–131 and a putative lower affinity domain between amino acids 321 and 470. J. Neurosci. Res. 62:764–771, 2000. © 2000 Wiley‐Liss, Inc.

[1]  E. Zwarthoff,et al.  Expression of the Neurofibromatosis Type 2 Gene in Human Tissues , 1999, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[2]  A. Vaheri,et al.  Homotypic and heterotypic interaction of the neurofibromatosis 2 tumor suppressor protein merlin and the ERM protein ezrin. , 1999, Journal of cell science.

[3]  M. Nakao,et al.  Impairment of cell adhesion by expression of the mutant neurofibromatosis type 2 (NF2) genes which lack exons in the ERM-homology domain , 1998, Oncogene.

[4]  M. Nakao,et al.  The involvement of calpain-independent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas , 1998, Nature Medicine.

[5]  K. Pestonjamasp,et al.  Merlin differs from moesin in binding to F-actin and in its intra- and intermolecular interactions. , 1998, Biochemical and biophysical research communications.

[6]  S. Pulst,et al.  Neurofibromatosis 2 tumour suppressor schwannomin interacts with βII-spectrin , 1998, Nature Genetics.

[7]  T. Jacks,et al.  Localization and functional domains of the neurofibromatosis type II tumor suppressor, merlin. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[8]  P. Riegman,et al.  A G-->A transition creates a branch point sequence and activation of a cryptic exon, resulting in the hereditary disorder neurofibromatosis 2. , 1998, Human molecular genetics.

[9]  D. Gutmann,et al.  Merlin differentially associates with the microtubule and actin cytoskeleton , 1998, Journal of neuroscience research.

[10]  G. Thomas,et al.  Impaired interaction of naturally occurring mutant NF2 protein with actin-based cytoskeleton and membrane. , 1998, Human molecular genetics.

[11]  J. Gusella,et al.  NHE-RF, a Regulatory Cofactor for Na+-H+Exchange, Is a Common Interactor for Merlin and ERM (MERM) Proteins* , 1998, The Journal of Biological Chemistry.

[12]  D. Louis,et al.  Universal absence of merlin, but not other ERM family members, in schwannomas. , 1997, The American journal of pathology.

[13]  D. Gutmann,et al.  Interdomain binding mediates tumor growth suppression by the NF2 gene product , 1997, Oncogene.

[14]  J. Jääskeläinen,et al.  The ezrin protein family: membrane-cytoskeleton interactions and disease associations. , 1997, Current opinion in cell biology.

[15]  J. Jääskeläinen,et al.  Neurofibromatosis 2 tumor suppressor protein colocalizes with ezrin and CD44 and associates with actin-containing cytoskeleton. , 1997, Journal of cell science.

[16]  P. Mangeat,et al.  A Dual Involvement of the Amino-terminal Domain of Ezrin in F- and G-actin Binding* , 1997, The Journal of Biological Chemistry.

[17]  B. Korf,et al.  The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. , 1997, JAMA.

[18]  D. Gutmann,et al.  Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas , 1997, Neurology.

[19]  S. Pulst,et al.  Immunohistochemical Detection of Schwannomin and Neurofibromin in Vestibular Schwannomas, Ependymomas and Meningiomas , 1997, Journal of neuropathology and experimental neurology.

[20]  V. Sundaram,et al.  Reduced Expression of Schwannomin/Merlin in Human Sporadic Meningiomas , 1997 .

[21]  S. Tsukita,et al.  ERM proteins: head-to-tail regulation of actin-plasma membrane interaction. , 1997, Trends in biochemical sciences.

[22]  W. Ballhausen,et al.  Subcellular localization and expression pattern of the neurofibromatosis type 2 protein merlin/schwannomin. , 1997, European journal of cell biology.

[23]  D. Gutmann,et al.  Expression of the neurofibromatosis 2 tumor suppressor gene product, merlin, in Schwann cells , 1996, Journal of neuroscience research.

[24]  J. Gusella,et al.  The merlin tumor suppressor localizes preferentially in membrane ruffles. , 1996, Oncogene.

[25]  E. Zwarthoff.  Neurofibromatosis and associated tumour suppressor genes. , 1996, Pathology, research and practice.

[26]  T. H. van der Kwast,et al.  Neurofibromatosis type 2 protein co-localizes with elements of the cytoskeleton. , 1995, The American journal of pathology.

[27]  A. Bretscher,et al.  Ezrin self-association involves binding of an N-terminal domain to a normally masked C-terminal domain that includes the F-actin binding site. , 1995, Molecular biology of the cell.

[28]  T. H. van der Kwast,et al.  The product of the NF2 tumour suppressor gene localizes near the plasma membrane and is highly expressed in muscle cells. , 1995, Oncogene.

[29]  A. Vaheri,et al.  Ezrin has a COOH-terminal actin-binding site that is conserved in the ezrin protein family , 1994, The Journal of cell biology.

[30]  S. Pulst,et al.  Mutations of the neurofibromatosis type 2 gene and lack of the gene product in vestibular schwannomas. , 1994, Human molecular genetics.

[31]  J. Gusella,et al.  Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types , 1994, Nature Genetics.

[32]  B. Seizinger,et al.  Molecular cloning and characterization of alternatively spliced transcripts of the mouse neurofibromatosis 2 gene. , 1994, Cancer research.

[33]  A. Bretscher,et al.  Heterotypic and homotypic associations between ezrin and moesin, two putative membrane-cytoskeletal linking proteins. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[34]  S. Pulst,et al.  Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2 , 1993, Nature.

[35]  J. Haines,et al.  A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor , 1993, Cell.

[36]  A. Bretscher.  Rapid phosphorylation and reorganization of ezrin and spectrin accompany morphological changes induced in A-431 cells by epidermal growth factor , 1989, The Journal of cell biology.